Roivant Sciences Ltd. (ROIV) stock
ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
$36.91−0.61 (-1.63%)
Close on Oct 30, 2026Market cap $26.66BP/E –Yield –
Earnings
Roivant Sciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 9, 2026
Q2 FY2026 · estimated, before the open
Revenue, Q1 FY2026
$1.44M
-33.5% on a year earlier
EPS, Q1 FY2026
-$0.26
-$0.33 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Roivant Sciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q2 FY2026ended Sep 30, 2026 | Nov 9, 2026Expected | – | – | – | – |
| Q1 FY2026ended Jun 30, 2026 | Aug 6, 2026before the open | $1.44M | -33.5% | -$0.26 | Release |
| Q4 FY2025ended Mar 31, 2026 | May 20, 2026before the open | $2.52M | -66.7% | $0.28 | Release |
| Q3 FY2025ended Dec 31, 2025 | Feb 6, 2026before the open | – | – | – | Release |
| Q2 FY2025ended Sep 30, 2025 | Nov 10, 2025before the open | $1.57M | – | -$0.17 | Release |
| Q1 FY2025ended Jun 30, 2025 | Aug 11, 2025before the open | $2.17M | -96.1% | -$0.33 | Release |
| Q4 FY2024ended Mar 31, 2025 | May 29, 2025before the open | $7.57M | -73.8% | -$0.29 | Release |
| Q3 FY2024ended Dec 31, 2024 | Feb 10, 2025before the open | – | – | – | Release |
| Q2 FY2024ended Sep 30, 2024 | Nov 12, 2024before the open | – | – | – | Release |
| Q1 FY2024ended Jun 30, 2024 | Aug 8, 2024before the open | $55.13M | +155.0% | $0.12 | Release |
| Q4 FY2023ended Mar 31, 2024 | May 30, 2024before the open | $28.93M | +5.7% | -$0.19 | Release |
| Q3 FY2023ended Dec 31, 2023 | Feb 13, 2024before the open | $37.14M | +117.8% | $6.03 | Release |
| Q2 FY2023ended Sep 30, 2023 | Nov 13, 2023before the open | $37.10M | +196.0% | -$0.40 | Release |
| Q1 FY2023ended Jun 30, 2023 | Aug 14, 2023before the open | $21.62M | +400.7% | -$0.38 | Release |
| Q4 FY2022ended Mar 31, 2023 | Jun 28, 2023before the open | $27.38M | +196.8% | -$0.05 | Release |
| Q3 FY2022ended Dec 31, 2022 | Feb 13, 2023before the open | $17.05M | -29.9% | -$0.49 | Release |
| Q2 FY2022ended Sep 30, 2022 | Nov 14, 2022before the open | $12.53M | -10.4% | -$0.42 | Release |
| Q1 FY2022ended Jun 30, 2022 | Aug 15, 2022before the open | $4.32M | – | -$0.48 | Release |
| Q4 FY2021ended Mar 31, 2022 | Jun 28, 2022before the open | $9.22M | – | -$0.39 | Release |
| Q3 FY2021ended Dec 31, 2021 | Feb 14, 2022before the open | $24.34M | – | -$0.41 | Release |
| Q2 FY2021ended Sep 30, 2021 | Nov 15, 2021before the open | $13.99M | – | -$0.32 | Release |
| Q1 FY2021ended Jun 30, 2021 | Sep 21, 2021after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Roivant Sciences has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Roivant Sciences puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Roivant Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- Update
- Results
- Results
- Results
- Update
- Update
- Results
- Update
- Update
- Results
- Update
- Update